Cardio-vascular
Refine Search
Pharmaceutical
Drugs used in the treatment of cardiovascular diseases are the key group of pharmaceuticals – in 2014, the value of sales of cardiac medications in Poland reached 4.3 billion zlotys ($1.15 billion or 1.0 billion euros, in retail prices). 9 April 2015
Pharmaceutical
German drug major Bayer has extended its collaboration with the Broad Institute of MIT and Harvard to include cardiovascular genomics and drug discovery. 9 April 2015
Pharmaceutical
Taxus Cardium Pharmaceuticals Group has entered into a binding term sheet with India’s Dr Reddy's Laboratories for an exclusive territorial license covering the co-development, marketing and sales of Generx 7 April 2015
Biotechnology
Dutch biotech firm uniQure saw its shares rocket more than 52% to $34.42 this morning, after it revealed a multi-million agreement with US pharma major Bristol-Myers Squibb that could result in payements in excess of $2.2 billion for uniQure. 6 April 2015
Generics
US drugmaker The Medicines Company says it has settled its litigation with India’s Sun Pharmaceutical Industries and certain of its subsidiaries relating to MDCO’s US patents covering the anticoagulant Angiomax (bivalirudin). 2 April 2015
Generics
Israeli generics giant Teva Pharmaceutical Industries says it has launched a generic equivalent to Exforge (amlodipine and valsartan) tablets in four different strengths, in the USA. 31 March 2015
Pharmaceutical
German pharma major Bayer says it has expanded its collaboration with the USA’s Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard University. 31 March 2015
Pharmaceutical
The Medicines Company (Nasdaq: MDCO) said yesterday that the European Commission has granted marketing authorization for three of its hospital acute care products, and the firm is looking for partners. 31 March 2015
Biotechnology
French active ingredients company Novasep and US biotech firm Celladon Corp, a clinical-stage cardiovascular gene therapy company, have signed a development, manufacturing and supply agreement under which, if supported by upcoming Mydicar clinical data, Novasep would manufacture Mydicar (AAV1/SERCA2a) drug substance through 2018 with extension options through 2020. 26 March 2015
Pharmaceutical
The US Food and Drug Administration is warning that serious slowing of the heart rate can occur when the antiarrhythmic drug amiodarone is taken together with either the hepatitis C drug Harvoni (ledipasvir/sofosbuvir) or with Sovaldi (sofosbuvir) taken in combination with another direct acting antiviral for the treatment of hepatitis C infection. 25 March 2015
Pharmaceutical
The National Institute of Health and Care Excellence (NICE), the medicines cost watchdog for England and Wales, today announced several National Health Service funding decisions. 25 March 2015
Biotechnology
US health care giant Johnson & Johnson subsidiary Janssen Pharmaceuticals, has acquired XO1 Limited, a UK-based privately held asset-centric virtual biopharmaceutical company. 24 March 2015
Pharmaceutical
High cholesterol itself is not a disease, but it can lead to serious health consequences, according to an article by Holly Campbell, director of communications at Pharmaceutical Research and Manufacturers of America (PhRMA). 23 March 2015
Biotechnology
Leading USA-based biotech firm Amgen has filed for approval of Repatha (evolocumab) for the treatment of high cholesterol has been submitted for review to the Ministry of Health, Labor and Welfare in Japan. 20 March 2015
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca released much anticipated trial results for its blood-thinning drug Brilinta (ticagrelor) at the American College of Cardiology meeting, which were simultaneously published in the New England Journal of Medicine. 16 March 2015
Pharmaceutical
Results of a new study published in the New England Journal of Medicine have shown that the experimental PCSK9 inhibitors being developed by Amgen, Sanofi and Regeneron reduce the risk of cardiovascular events by around half. 16 March 2015
Generics
Privately-held Breckenridge Pharmaceutical has filed an Abbreviated New Drug Application with a Paragraph IV certification for dabigatran etexilate mesylate capsules, a generic of Pradaxa from Boehringer Ingelheim. 13 March 2015
Pharmaceutical
Anglo-Swedish drug major AstraZeneca is to undertake a two-year collaboration with leading organizations in Singapore, including the Agency for Science, Technology and Research and the National University of Singapore, to support research into new heart failure therapies. 11 March 2015
Pharmaceutical
In draft guidance published today, the National Institute for Health and care Excellence (NICE), the medical costs watchdog for England, has recommended the anti-blood clotting drug Eliquis (apixaban), from US pharma majors Bristol-Myers Squibb and Pfizer as a National Health Service option for treating and preventing venous thromboembolism (VTE) in adults. 6 March 2015
Biotechnology
Belgian cell therapy specialist Cardio3 BioSciences has received a Pediatric Investigation Plan (PIP) waiver from the European Medicines Agency for C-Cure, the Company’s lead product-candidate currently in Phase III clinical development for the treatment of ischemic heart failure. 3 March 2015
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Johnson & Johnson has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase year-over-year. 15 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze